Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia

Stopped For business reason unrelated to safety or tolerability,Tonix discontinued this study.

Conditions

• Fibromyalgia
• Myofascial Pain Syndromes
• Muscular Diseases
• Nervous System Diseases
• Neuromuscular Diseases
• Rheumatic Diseases
• Musculoskeletal Diseases

Interventions

• DRUG: TNX-102 SL Tablet, 2.8 mg
• DRUG: Placebo SL Tablet

Sponsor

Tonix Pharmaceuticals, Inc.